Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Steroids in a Combination Strategy

  • Chapter
  • First Online:
Intravitreal Steroids

  • 609 Accesses

Abstract

Corticosteroids have emerged as a popular treatment option for the management of several retinal and choroidal pathologies, including neovascular age-related macular degeneration and macular edema secondary to diabetes and retinal vein occlusion. Intravitreal steroids have been widely studied in many randomized clinical trials demonstrating significant improvements either in morphological and functional outcomes, due to well-known antiangiogenic, antiedematous, anti-inflammatory, antiapoptotic, and antiproliferative effects. Recent advances in ocular drug delivery methods led to the development of intraocular implants, which help to provide prolonged treatment with controlled drug release. The use of intravitreal steroids as adjunctive therapy may add some potential benefits over other intraocular therapeutic agents by widening the spectrum of action, amplifying the therapy’s duration, and avoiding the side effects associated with repeated intravitreal injections by reducing the number of treatments required. The aim of this chapter is to provide a review on the use of intravitreal steroids in a combination strategy as a treatment alternative for a variety of retinal diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486–94.

    Article  CAS  PubMed  Google Scholar 

  2. Kang BS, Chung EY, Yun YP, et al. Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. Biol Pharm Bull. 2001;24(6):701–3.

    Article  CAS  PubMed  Google Scholar 

  3. Umland SP, Nahrebne DK, Razac S, et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-γ production by cultured primary CD4+ T cells. J Allergy Clin Immunol. 1997;100(4):511–9.

    Article  CAS  PubMed  Google Scholar 

  4. Floman N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. IOVS. 1977;16(1):69–73.

    CAS  Google Scholar 

  5. Tunc M, Onder HI, Kaya M. Posterior sub-Tenon’s capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Ophthalmology. 2005;112:1086–91.

    Article  PubMed  Google Scholar 

  6. Se WK, Sa HS, Hee YC, et al. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006;124(5):653–8.

    Article  Google Scholar 

  7. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006;124:653–8.

    Article  CAS  PubMed  Google Scholar 

  8. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140:695–702.

    Article  CAS  PubMed  Google Scholar 

  9. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology. 2007;114:2162–7.

    Article  PubMed  Google Scholar 

  10. Gillies MC, McAllister IL, Zhu M, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology. 2011;118:866–72.

    Article  PubMed  Google Scholar 

  11. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–77.

    Article  Google Scholar 

  12. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Choi KS, Chung JK, Lim SH. Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema. Korean J Ophthalmol. 2007;21:11–7.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Kaderli B, Avci R, Gelisken O, et al. Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO. Int Ophthalmol. 2007;26:207–14.

    Article  Google Scholar 

  15. Zacks DN, Johnson MW. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic retinopathy. Retina. 2005;25:135–40.

    Article  PubMed  Google Scholar 

  16. Zein WM, Noureddin BN, Jurdi FA, et al. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina. 2006;26:137–42.

    Article  PubMed  Google Scholar 

  17. Bandello F, Polito A, Pognuz DR, et al. Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol. 2006;124:643–50.

    Article  CAS  PubMed  Google Scholar 

  18. Maia OO, Takahashi BS, Costa RA. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol. 2009;147:291–7.

    Article  CAS  PubMed  Google Scholar 

  19. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol. 2005;19:122–7.

    Article  PubMed  Google Scholar 

  20. Jonas JB, Degenring R, Vossmerbauemer U, et al. Frequency of cataract surgery after intravitreal injection of high-dosage triamcinolone acetonide. Eur J Ophthalmol. 2005;15:462–4.

    CAS  PubMed  Google Scholar 

  21. Lang Y, Zemel E, Miller B, et al. Retinal toxicity of intravitreal kenalog in albino rabbits. Retina. 2007;27:778–88.

    Article  PubMed  Google Scholar 

  22. Callanan DG, Gupta S, Boyer DS, Ozurdex PLACID Study Group, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology. 2013;120(9):1843–51.

    Article  PubMed  Google Scholar 

  23. Polito A, Pognuz DR, Lanzetta P, et al. Intravitreal triamcinolone as adjunctive treatment to laser photocoagulation for cystoid macular edema due to branch retinal vein occlusion. In: Abstracts of annual ARVO meeting, Fort Lauderdale, 1–4 May 2006.

    Google Scholar 

  24. Sakamoto T, Shimura M, Yasuda K, et al. Combination therapy for retinal vein occlusion. Ophthalmology. 2010;117:1858.e1–3.

    Google Scholar 

  25. Riese J, Loukopoulos V, Meier C, Timmermann M, Gerding H. Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2008;246(12):1671–6.

    Article  CAS  PubMed  Google Scholar 

  26. Fernandes JK, Patel R, Hariprasad SM. Combination therapy of an intravitreal dexamethasone implant (OzurdexTM) plus prompt focal laser for macular edema secondary to retinal vein occlusions – 12 month follow-up. In: Abstracts of annual ARVO meeting, Fort Lauderdale, May 2012.

    Google Scholar 

  27. Parodi MB, Iacono P, Ravalico G. Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol. 2008;92(8):1046–50.

    Article  CAS  PubMed  Google Scholar 

  28. Cetin EN, Scanlon C, Akduman L. Outcomes of combined treatment with Ozurdex implant and grid laser photocoagulation for macular edema in branch retinal vein occlusion. In: Abstracts of annual ARVO meeting, Fort Lauderdale, May 2012.

    Google Scholar 

  29. Pichi F, Specchia C, Vitale L, et al. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. Am J Ophthalmol. 2014;157:607–15.

    Article  CAS  PubMed  Google Scholar 

  30. Ruiz-Moreno JM, Schmidt-Erfurth U. Photodynamic therapy and high dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina. 2006;26:602–12.

    Article  PubMed  Google Scholar 

  31. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301–4.

    Article  PubMed  Google Scholar 

  32. Arias L, Garcia-Arumi J, Ramon JM, et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of randomized study. Ophthalmology. 2006;113:2243–50.

    Article  PubMed  Google Scholar 

  33. Augustin AJ, Schmidt-Erfurth U. Verteporfin photodynamic combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:14–22.

    Article  PubMed  Google Scholar 

  34. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;141:638–45.

    Article  CAS  PubMed  Google Scholar 

  35. Russel SR, Hudson HL, Jerdan JA, et al. Anecortave acetate for the treatment of exudative age-related macular degeneration: a review of clinical outcomes. Surv Ophthalmol. 2007;52:79–90.

    Article  Google Scholar 

  36. Chaudhary V, Mao A, Hooper PL, et al. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology. 2007;114(12):2183–9.

    Article  PubMed  Google Scholar 

  37. Frimpong-Boateng A, Bunse A, Rüfer F, et al. Photodynamic therapy with intravitreal application of triamcinolone acetonide in age-related macular degeneration: functional results in 54 patients. Acta Ophthalmol. 2009;87:183–7.

    Article  CAS  PubMed  Google Scholar 

  38. Becerra EM, Morescalchi F, Gandolfo F, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011;12(2):149–72.

    Article  CAS  PubMed  Google Scholar 

  39. Piermarocchi S, Sartore M, Lo Giudice G, Maritan V, Midena E, Segato T. Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy. Arch Ophthalmol. 2008;126(10):1367–74.

    Article  PubMed  Google Scholar 

  40. Nowak-Sliwinska P, Weiss A, Sickenberg M, et al. The role of photodynamic therapy in non-malignant and malignant eye disorders. J Anal Bioanal Tech. 2013;S1:007. doi:10.4172/2155-9872.S1-007.

    Google Scholar 

  41. Pece A, Russo G, Ricci F, Isola V, Introini U, Querques G. Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks. Clin Ophthalmol. 2010;4:525–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Rishi P, Rishi E, Venkataraman A, et al. Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia. Indian J Ophthalmol. 2011;59:242–6.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116(6):1142–50.

    Article  PubMed  Google Scholar 

  44. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483–9.

    Article  CAS  PubMed  Google Scholar 

  45. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18:941–8.

    CAS  PubMed  Google Scholar 

  46. Sheth S, Rush R, Natarajan S, Gillies M. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Clin Exp Ophthalmol. 2011;39(7):673–81.

    Article  Google Scholar 

  47. Ford JA, Lois N, Royle P, Clar C, et al. Current treatments in diabetic macular oedema : systematic review and meta-analysis. BMJ Open. 2013;3:e002269.

    PubMed Central  PubMed  Google Scholar 

  48. Goyal S, LaValley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema Graefe’s archive for clinical and experimental. Ophthalmology. 2011;249:15–27.

    CAS  Google Scholar 

  49. Ekdawi NS, Bakri SJ. Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. Eye. 2007;21:1128–30.

    Article  CAS  PubMed  Google Scholar 

  50. Ehrlich R, Ciulla TA, Moss AM, Harris A. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol. 2010;248:375–80.

    Article  CAS  PubMed  Google Scholar 

  51. Cekiç O, Cakır M, Yazıcı AT, et al. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res. 2010;35(10):925–9.

    Article  PubMed  Google Scholar 

  52. Lee K, Jung H, Sohn J. Comparison of injection of intravitreal drugs with standard care in macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2014;28(1):19–25.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Singer MA, Bell DJ, Woods P, et al. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion. Retina. 2012;32(7):1289–94.

    CAS  PubMed  Google Scholar 

  54. Mayer WJ, Remy M, Wolf A, et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica. 2012;228(2):110–6.

    Article  CAS  PubMed  Google Scholar 

  55. Mayer WJ, Wolf A, Kernt M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye. 2013;27(7):816–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  56. Veritti D, Sarao V, Lanzetta P. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors. J Ocul Pharmacol Ther. 2013;29(4):437–41.

    Article  CAS  PubMed  Google Scholar 

  57. El Matri L, Chebil A, Kort F, Bouraoui R, Baklouti K, Mghaieth F. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248:779–84.

    Article  PubMed  Google Scholar 

  58. Loewenstein A, Kuppermann BD, Weinberger D, et al. Safety and efficacy of Ozurdex (dexamethasone intravitreal implant) as adjunctive therapy to Lucentis in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Paper presented at: Association for Research in Vision and Ophthalmology, Fort Lauderdale, 3 May 2010.

    Google Scholar 

  59. Singer M, Patel SS, Uy HS, Li X-Y, Liu C-C, Whitcup SM. Dexamethasone intravitreal implant alone and as an adjunct to ranibizumab for the treatment of choroidal neovascularization secondary to age-related macular degeneration. Paper presented at: Retina Society annual meeting, Rome, 22–25 Sept 2011.

    Google Scholar 

  60. Ranchod TM, Ray SK, Daniels SA, Leong CJ, Ting TD, Verne AZ. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. Retina. 2013;33(8):1600–4.

    Article  CAS  PubMed  Google Scholar 

  61. Agustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:133–40.

    Article  Google Scholar 

  62. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina. 2009;29:573–8.

    Article  PubMed  Google Scholar 

  63. Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol. 2007;7:10.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Yip PP, Woo CF, Tang HH, Ho CK. Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol. 2009;93:754–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Forte R, Bonavolonta P, Benayoun Y, Adenis JP, Robert PY. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration. Ophthalmic Res. 2011;45:129–34.

    Article  CAS  PubMed  Google Scholar 

  66. Ehmann D, Garcia R. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Can J Ophthalmol. 2010;45:36–40.

    Article  PubMed  Google Scholar 

  67. Hudson H. RADICAL: 24-month results of a phase II exploratory randomized clinical trial of reduced fluence vPDT-anti-VEGF-dexamethasone in AMD. Paper presented at: annual meeting of the American Society of Retinal Specialists, Vancouver, 28 Aug–1 Sept 2010.

    Google Scholar 

  68. Veritti D, Lanzetta P. Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters. Ophthalmologica. 2013;230(3):131–7.

    Article  CAS  PubMed  Google Scholar 

  69. Lonngi M, Gold AS, Murray TG. Combined bevacizumab and triamcinolone acetonide injections for macular edema in a patient with astrocytic hamartomas and tuberous sclerosis. Ophthal Surg Lasers Imaging Retin. 2013;44(1):85–90.

    Article  Google Scholar 

  70. Böhm MR, Uhlig CE. Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249(7):1099–101.

    Article  PubMed  Google Scholar 

  71. Shah NV, Houston SK, Markoe A, Murray TG. Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma. Clin Ophthalmol. 2013;7:1877–82.

    PubMed Central  CAS  PubMed  Google Scholar 

  72. Saeed AM. Combined vitrectomy and intravitreal injection versus combined laser and injection for treatment of intractable diffuse diabetic macular edema. Clin Ophthalmol. 2013;7:283–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. Koss MJ, Naser H, Sener A, et al. Combination therapy in diabetic macular oedema and retinal vein occlusion–past and present. Acta Ophthalmol. 2012;90(6):580–9.

    Article  PubMed  Google Scholar 

  74. Jin M, Ke Y, Zheng Z, Xiajing T. Twenty-five-gauge vitrectomy and triamcinolone acetonide-assisted internal limiting membrane peeling for chronic macular edema associated with branch retinal vein occlusion. Retina. 2008;28:947–56.

    Article  Google Scholar 

  75. Uemura A, Yamamoto S, Sato E, et al. Vitrectomy alone versus vitrectomy with simultaneous injection of triamcinolone for macular edema associated with branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2009;40:6–12.

    Article  PubMed  Google Scholar 

  76. Opremcak EM, Rehmar AJ, Ridenour CD, et al. Radial optic neurotomy with adjunctive intraocular triamcinolone for central retinal vein occlusion: 63 consecutive cases. Retina. 2006;26:306–31.

    Article  PubMed  Google Scholar 

  77. Garcia-Arumi J, Boixedera A, Martinez-Castillo V, et al. Chorioretinal anastomosis alter radial optic neurotomy for central retinal vein occlusion. Arch Ophthalmol. 2003;121:1385–91.

    Article  Google Scholar 

  78. Oono Y, Tsuru H, Teruya K, et al. Long-term outcomes of radial optic neurotomy with or without adjunctive intraocular triamcinolone acetonide in central retinal vein occlusion. In: Abstracts of annual ARVO meeting, Fort Lauderdale, May 2008.

    Google Scholar 

  79. Hwang JC, Gelman SK, Fine HF, Chang S, Del Priore LV. Combined arteriovenous sheathotomy and intraoperative intravitreal triamcinolone acetonide for branch retinal vein occlusion. Br J Ophthalmol. 2010;94(11):1483–9.

    Article  PubMed  Google Scholar 

  80. Ferrari TM, Sborgia L, Furino C, et al. Radial optic neurotomy, internal limiting membrane peeling and intravitreal triamcinolone in the occlusion of the central retinal vein occlusion. In: Abstracts of annual ARVO meeting, Fort Lauderdale, May 2004.

    Google Scholar 

  81. Fortunato P, Pollazzi L, Baroni M, et al. Venous retinal flow reperfusion mechanisms following radial optic neurotomy with adjunctive intraocular triamcinolone in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248:167–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  82. Serny C, Mura F, Rebollo B, et al. Hemodilution with and without triamcinolone at the initial phase of vein occlusion: a retrospective comparative study. In: Abstracts of annual ARVO meeting, Fort Lauderdale, May 2007.

    Google Scholar 

  83. Lewis GM, Morris R. Treatment of cystoid macular edema in branch retinal vein occlusion with grid photocoagulation, intravitreal triamcinolone, and pneumatic maculopexy. In: Abstracts of annual ARVO meeting, Fort Lauderdale, May 2006.

    Google Scholar 

  84. Gutfleisch M, Spital G, Mingels A, Pauleikhoff D, Lommatzsch A, Heiligenhaus A. Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol. 2007;91(3):345–8.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Biological Sciences – Ophthalmology, University of Udine, P.le S.M. della Misericordia, 33100, Udine, Italy

    Paolo Lanzetta MD, Daniele Veritti MD & Valentina Sarao MD

  2. Istituto Europeo di Microchirugia Oculare – IEMO, Via M.A. Fiducio, 8, 33100, Udine, Italy

    Paolo Lanzetta MD & Daniele Veritti MD

Authors
  1. Paolo Lanzetta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniele Veritti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Sarao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Paolo Lanzetta MD or Daniele Veritti MD .

Editor information

Editors and Affiliations

  1. Städt. Klinikum Karlsruhe, Augenklinik, Karlsruhe, Germany

    Albert J. Augustin

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lanzetta, P., Veritti, D., Sarao, V. (2015). Steroids in a Combination Strategy. In: Augustin, A. (eds) Intravitreal Steroids. Springer, Cham. https://doi.org/10.1007/978-3-319-14487-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14487-0_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14486-3

  • Online ISBN: 978-3-319-14487-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation